A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 2, Pages 393-402
Publisher
Springer Nature
Online
2016-08-01
DOI
10.1038/leu.2016.215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin-6 as a Therapeutic Target
- (2015) J.-F. Rossi et al. CLINICAL CANCER RESEARCH
- A comprehensive review of pacritinib in myelofibrosis
- (2015) Srdan Verstovsek et al. Future Oncology
- Novel therapies for myelofibrosis
- (2015) Brady L. Stein et al. LEUKEMIA & LYMPHOMA
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- JAK/STAT Pathway Inhibitors and Neurologic Toxicity
- (2015) Bart L. Scott et al. JAMA Oncology
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- How many JAK inhibitors in myelofibrosis?
- (2014) Bruna Velosa Ferreira et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
- (2014) M. Cazzola et al. BLOOD
- How I treat myelofibrosis
- (2014) F. Cervantes BLOOD
- The future of JAK inhibition in myelofibrosis and beyond
- (2014) John O. Mascarenhas et al. BLOOD REVIEWS
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
- (2014) Ramy A. Abdelrahman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
- (2014) Y Nakaya et al. Blood Cancer Journal
- Definition and management of ruxolitinib treatment failure in myelofibrosis
- (2014) A Pardanani et al. Blood Cancer Journal
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- The role of cytokines in the initiation and progression of myelofibrosis
- (2013) Hans C. Hasselbalch CYTOKINE & GROWTH FACTOR REVIEWS
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT3 in Colon Cancer Cells
- (2011) K. E. Hamilton et al. MOLECULAR CANCER RESEARCH
- Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms
- (2011) Y Nakaya et al. Blood Cancer Journal
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
- (2010) T. Barbui et al. HAEMATOLOGICA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
- (2009) Ruben A. Mesa et al. LEUKEMIA RESEARCH
- How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis
- (2009) Alessandro M. Vannucchi LEUKEMIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started